Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211018028
Abstract: Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known to occur with osimertinib.… read more here.
Keywords: induced pneumonitis; steroid protection; osimertinib induced; osimertinib ... See more keywords